ArticleMaterials today. Bio2026
Development of polypeptide scaffold for anti-endometrial invasion and ordered myometrial recovery in uterine diverticulum.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Injectable ROS-Responsive Nanozyme Hydrogel Regulates the Uterine Microenvironment to Prevent Intrauterine Adhesions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine diverticulum (UD) is characterized by localized thinning of the uterine myometrium, leading to the formation of recessed structures. While its mechanisms remain undefined, UD, often an aftermath of cesarean sections, mandates subsequent surgical intervention, highlighting the critical need for intraoperative prevention. Drawing inspiration from the natural anatomical structure of the uterus, we developed biomimetic, anisotropic, multi-channel silk fibroin-based uterine bioscaffolds (BSBs). The BSBs, characterized by aligned fibrous structures and hollow channels, significantly promoted the orderly directional growth of uterine smooth muscle cells and enhanced the infiltration of human umbilical vein endothelial cells. Single-cell RNA sequencing (scRNA-seq) analysis of endometrial tissue affected by UD suggested that ectopic invasion of the endometrial tissue might contribute to UD formation. The BSBs incorporated bioactive polypeptides identified through scRNA-seq with exosomes derived from autologous menstrual blood stem cells, creating a composite scaffold (BSBs@exo@poly) designed to avert UD onset. In a rat model of uterine injury, treatment with BSBs@exo@poly effectively suppressed ectopic endometrial tissue invasion, guided the organized reconstruction of muscle fibers, and supported endometrial regeneration, thereby accelerating the restoration of normal uterine morphology and attenuation of inflammation. Therefore, BSBs@exo@poly presents an innovative and promising therapeutic strategy for the treatment of uterine damaged conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.